Completed PHASE2 INTERVENTIONAL 1-arm NCT00005622

Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Allogeneic Bone Marrow Transplantation Using Closely Matched Related and Unrelated Donors

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Conditions Chronic Myeloproliferative Disorders Leukemia Multiple Myeloma and Malignant Plasma Cell Neoplasms Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms

Interventions TBI cyclophosphamide

Updated 6 times since 2017 Last updated: Oct 24, 2012 Started: May 31, 1996 Primary completion: Sep 30, 2005 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Myeloproliferative Disorders and Leukemia and is currently completed. H. Lee Moffitt Cancer Center and Research Institute leads this study, which shows 6 recorded versions since 1996 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tampa, United States